` TBP (Tetra Bio Pharma Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

TBP
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, TBP has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +21% growth.

Stocks Performance
TBP vs S&P TSX Composite Index (Canada)

Loading
TBP
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
TBP vs S&P TSX Composite Index (Canada)

Loading
TBP
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
TBP vs S&P TSX Composite Index (Canada)

Loading
TBP
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
Tetra Bio Pharma Inc vs Peers

S&P TSX Composite Index (Canada)
TBP
LLY
JNJ
ROG
AZN
Add Stock

Tetra Bio Pharma Inc
Glance View

Market Cap
10.6m CAD
Industry
Pharmaceuticals

Tetra Bio-Pharma, Inc. engages in the discovery and development of cannabinoid-based drugs and treatments. The company is headquartered in Orleans, Ontario and currently employs 33 full-time employees. The company went IPO on 2008-04-15. The firm is engaged in the development of bio pharmaceuticals and natural health products containing cannabis and other medicinal plant-based elements. The firm is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. The firm's objective is to bring prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acute Respiratory Distress Syndrom (ARDS), sepsis and ophthalmic disease. Its products include QIXLEEF, CAUMZ, REDUVO Capsules, REDUVO Adversa, ARDS-003 and PPP-002. Its QIXLEEF is a botanical inhaled drug with a fixed ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD).

TBP Intrinsic Value
Not Available
Back to Top